Eli Lilly revs up immunology engine as Olumiant cruises toward coveted alopecia green light

Immunology may be the youngest of Eli Lilly’s business units, but the Indianapolis-based pharma expects to have skin in the game for years to come.

When Lilly carved out its immunology unit last year, the company made a “long-term commitment” to the field, operating under the assumption it had a portfolio of products “not just today, but at least for the coming decade or decades,” Patrik Jonsson, the company’s immunology president and president of Lilly USA, said during a recent sit-down in New York.